563 related articles for article (PubMed ID: 34263255)
1. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors for urothelial carcinoma.
Kim HS; Seo HK
Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives.
Roviello G; Catalano M; Santi R; Palmieri VE; Vannini G; Galli IC; Buttitta E; Villari D; Rossi V; Nesi G
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503220
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
6. Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
9. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions.
Gupta S; Gill D; Poole A; Agarwal N
Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134806
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
12. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
Meeks JJ; Black PC; Galsky M; Grivas P; Hahn NM; Hussain SA; Milowsky MI; Steinberg GD; Svatek RS; Rosenberg JE
Eur Urol; 2023 Nov; 84(5):473-483. PubMed ID: 37258363
[TBL] [Abstract][Full Text] [Related]
14. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
Lenfant L; Aminsharifi A; Seisen T; Rouprêt M
Curr Opin Urol; 2020 May; 30(3):428-440. PubMed ID: 32141936
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
García-Perdomo HA; Sánchez AL; Spiess PE
Urol Oncol; 2022 Sep; 40(9):409.e1-409.e8. PubMed ID: 35232680
[TBL] [Abstract][Full Text] [Related]
16. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma.
Seront E; Catala G; Dermine A; Lejeune S; Rysselinck S
Future Sci OA; 2018 Dec; 4(10):FSO341. PubMed ID: 30457576
[TBL] [Abstract][Full Text] [Related]
18. Overview, Diagnosis, and Perioperative Systemic Therapy of Upper Tract Urothelial Carcinoma.
Kolawa A; D'Souza A; Tulpule V
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835507
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
20. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
Ghatalia P; Zibelman M; Geynisman DM; Plimack E
Ther Adv Med Oncol; 2018; 10():1758835918788310. PubMed ID: 30083254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
